HR and breast cancer: A clinical trial evaluating inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with HR+, HER2–, PIK3CA-mutated locally advanced or metastatic BC is ongoing (NCT05646862, INAVO121).